Ultragenyx CEO and Founder Discusses Fundamental Flaws in Drug Development Process

Emil Kakkis, MD, Ph.D., founder and CEO of Ultragenyx sat down for an interview with Larry Luxner, senior correspondent for Rare Disease Advisor. Dr. Kakkis spoke about the inefficiency and often lack of effectiveness of the current development paradigm.

In the interview, Dr. Kakkis explains why biomarkers instead of clinical endpoints should be the determining factor for the efficacy of any given therapy.

Read the original article.